Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts

Jiunn Chang Lin, Wei Pang Huang, Chien Liang Liu, Jie Jen Lee, Tsang Pai Liu, Wen Chin Ko, Yu Chuen Huang, Ming Ling Hsu, Chih Hsiung Wu, Yu Jen Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Sorafenib, a multikinase inhibitor approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has been reported inhibitory on the function of dendritic cells. This study was aimed to determine the effects of sorafenib on inducing autophagy and immunomodulatory activity and its implication on graft rejection. Methods. Cell viability and surface antigens were examined by 7-amino-actinomycin D and flow cytometric analysis. Autophagy was characterized using light microscopy and transmission electron microscopy for morphology, Western blotting for LC3B-I lipidation and mammalian target of rapamycin signaling molecules, and immunofluorescence staining for endogenous LC3B, GFP-LC3 transfection, and acidic component vacuoles. Skin allograft in mice was used as an experimental transplantation rejection model. Soluble factors contained in culture medium and serum were measured by enzyme-linked immunosorbent assay. Results. We found that sorafenib inhibited the viability of dendritic cells accompanied by morphologic changes characteristic of autophagy and immature differentiation. This autophagic effect induced by sorafenib was validated by LC3B-I lipidation and autophagosome accumulation. Sorafenib treatment was associated with the down-regulation of phosphorylated mammalian target of rapamycin and its downstream substrate p70S6K. We next performed skin graft model to testify the role of sorafenib-induced immature and autophagic dendritic cells. Intriguingly, sorafenib prolonged the survival of skin allograft without major toxicity. Blockade of autophagic flux by chloroquine partially diminished the protective effect of sorafenib, indicating an autophagy-related mechanism in vivo. Conclusion. This study suggests that sorafenib, in addition to being an anticancer agent, may have potential to be developed as a new category of immunosuppressant drugs acting via autophagy induction of dendritic cells.

Original languageEnglish
Pages (from-to)791-800
Number of pages10
JournalTransplantation
Volume95
Issue number6
DOIs
Publication statusPublished - May 27 2013

    Fingerprint

Keywords

  • Allograft tolerance
  • Autophagy
  • Dendritic cell
  • mTOR
  • Sorafenib

ASJC Scopus subject areas

  • Transplantation

Cite this

Lin, J. C., Huang, W. P., Liu, C. L., Lee, J. J., Liu, T. P., Ko, W. C., Huang, Y. C., Hsu, M. L., Wu, C. H., & Chen, Y. J. (2013). Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. Transplantation, 95(6), 791-800. https://doi.org/10.1097/TP.0b013e31827fac48